Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nurix TherapeuticsNRIX +0.36%61 PS Ratio is 67.25 as of Aug. 06, 2026, which is 267% above its 10-year median of 18.32. GuruFocus rates NRIX with a GF Score™ of 61/100 and a GF Value™ of $6.40 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 929 Biotechnology companies, Nurix Therapeutics ranks worse than 82.02% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nurix Therapeutics's share price is $25.22.
Nurix Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was $0.38. Hence, Nurix Therapeutics's PS Ratio for today is 67.25.
Warning Sign:
Nurix Therapeutics Inc stock PS Ratio (=67.01) is close to 10-year high of 68.63.
The historical rank and industry rank for Nurix Therapeutics's PS Ratio or its related term are showing as below:
NRIX'
s PS Ratio Range Over the Past 10 Years
Min: 3.48 Med: 18.32 Max: 68.63
Current: 67.23
During the past 8 years, Nurix Therapeutics's highest PS Ratio was 68.63. The lowest was 3.48. And the median was 18.32.
NRIX's PS Ratio is ranked worse than 82.02% of 929
companies
in the Biotechnology industry
Industry Median: 9.25
vs NRIX: 67.23
Nurix Therapeutics Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Nurix Therapeutics was -65.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.70% per year.
During the past 8 years, Nurix Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 7.60% per year. The lowest was -33.20% per year. And the median was 5.40% per year.
Nurix Therapeutics (NAS:NRIX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Nurix Therapeutics PS Ratio Related Terms
Nurix Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Nurix Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nurix Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Nurix Therapeutics's Share Price of today is $25.22. Nurix Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.38.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Nurix Therapeutics (NRIX) has a PS Ratio of 67.25 as of Aug. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nurix Therapeutics and its competitors. This is 267% above median its historical median of 18.32. Over the past decade, Nurix Therapeutics' PS Ratio has ranged from 3.48 to 68.63. According to the industry distribution chart, Nurix Therapeutics ranks #762 out of 929 companies in the Biotechnology industry, placing it in the top 82%.
Is Nurix Therapeutics' PS Ratio too high?
Nurix Therapeutics' current PS Ratio of 67.25 is 267% above median its 10-year median of 18.32. Over the past 10 years, this metric has ranged from a low of 3.48 to a high of 68.63. The Biotechnology industry median PS Ratio is 9.25. Nurix Therapeutics' value of 67.25 is 627% above this industry median. Based on the distribution chart, Nurix Therapeutics ranks #762 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nurix Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' PS Ratio compare to PHVS and NKTR?
According to the Biotechnology industry distribution chart, Nurix Therapeutics ranks #762 out of 929 companies for PS Ratio. This places Nurix Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.25. Nurix Therapeutics' value of 67.25 is 627% above this benchmark. Historically, Nurix Therapeutics' own PS Ratio has ranged from 3.48 to 68.63 over the past decade. While the company's 10-year median is 18.32 vs. the industry median of 9.25, Nurix Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.25, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nurix Therapeutics's current PS Ratio of 67.25 is 627% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nurix Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nurix Therapeutics's current PS Ratio is 67.25, which is 267% above median its own 10-year median of 18.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.40, compared to a current price of $25.22 — trading 294.1% above its estimated fair value. The current PS Ratio is 67.25, which is 267% above median its 10-year median of 18.32 and 627% above the Biotechnology industry median of 9.25. Nurix Therapeutics' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current PS Ratio is 67.25 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nurix Therapeutics (NRIX) Overvalued in 2026?
Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued.
The current stock price of $25.22 is trading 294.1% above its estimated GF Value™ of $6.40.
GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.
Key valuation signals for NRIX:
PS Ratio: 67.25 (267% above median its 10-year median of 18.32)
GF Value™: $6.40 vs. price of $25.22 (294.1% above fair value)
Industry Position: 627% above the Biotechnology median (#762 of 929)
No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
61GF Score
Get the complete analysis for NRIX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRIX has been successfully added to your 
